JP4791975B2 - サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用 - Google Patents

サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用 Download PDF

Info

Publication number
JP4791975B2
JP4791975B2 JP2006547427A JP2006547427A JP4791975B2 JP 4791975 B2 JP4791975 B2 JP 4791975B2 JP 2006547427 A JP2006547427 A JP 2006547427A JP 2006547427 A JP2006547427 A JP 2006547427A JP 4791975 B2 JP4791975 B2 JP 4791975B2
Authority
JP
Japan
Prior art keywords
compound
substituted
compounds
cells
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006547427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516296A5 (enExample
JP2007516296A (ja
Inventor
ボコビッチ，ニコラス
クルーゲ，アーサー，エフ．
オールマン，クリス
マーシ，クリシュナ，ケイ．
ラム，シーヤ
ワン，チョンホー
ハン，チャンシン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix USA Inc
Original Assignee
Agennix USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix USA Inc filed Critical Agennix USA Inc
Publication of JP2007516296A publication Critical patent/JP2007516296A/ja
Publication of JP2007516296A5 publication Critical patent/JP2007516296A5/ja
Application granted granted Critical
Publication of JP4791975B2 publication Critical patent/JP4791975B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006547427A 2003-12-23 2004-12-21 サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用 Expired - Fee Related JP4791975B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US53187203P 2003-12-23 2003-12-23
US60/531,872 2003-12-23
US56013804P 2004-04-06 2004-04-06
US60/560,138 2004-04-06
US61648004P 2004-10-06 2004-10-06
US60/616,480 2004-10-06
PCT/US2004/043492 WO2005063765A1 (en) 2003-12-23 2004-12-21 Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Publications (3)

Publication Number Publication Date
JP2007516296A JP2007516296A (ja) 2007-06-21
JP2007516296A5 JP2007516296A5 (enExample) 2009-08-27
JP4791975B2 true JP4791975B2 (ja) 2011-10-12

Family

ID=34743691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547427A Expired - Fee Related JP4791975B2 (ja) 2003-12-23 2004-12-21 サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用

Country Status (12)

Country Link
US (1) US8097619B2 (enExample)
EP (1) EP1709051A1 (enExample)
JP (1) JP4791975B2 (enExample)
KR (1) KR101155883B1 (enExample)
AU (1) AU2004309415B2 (enExample)
BR (1) BRPI0418095A (enExample)
CA (1) CA2551640C (enExample)
EA (1) EA013117B1 (enExample)
IL (1) IL176543A0 (enExample)
MX (1) MXPA06007399A (enExample)
NO (1) NO20063186L (enExample)
WO (1) WO2005063765A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298292A3 (en) * 2004-06-18 2011-08-10 Agennix USA Inc. Kinase inhibitors for treating cancers
EP2019101A1 (en) 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
BRPI1107312B1 (pt) 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
JP7166252B2 (ja) 2016-11-30 2022-11-07 メディツィーニシェ・ウニヴェルジテート・インスブルック サイクリン依存性キナーゼ阻害剤としての３－アミノ－１，５－ジヒドロピラゾロ［３，４－ｄ］ピリミジン－４－オン

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211732A (en) 1965-10-12 Pyrazolob:x-d]pyrlil/hdines
CH398626A (de) 1960-05-11 1966-03-15 Ciba Geigy Verfahren zur Herstellung neuer Pyrazolopyrimidine
JPS60130521A (ja) 1983-12-19 1985-07-12 Morishita Seiyaku Kk 抗癌剤
US4678499A (en) 1985-03-11 1987-07-07 E. I. Du Pont De Nemours And Company Herbicidal sulfonamides
JPS6299361A (ja) 1985-10-25 1987-05-08 Morishita Seiyaku Kk インデノ〔１，２−ｃ〕ピラゾ−ル誘導体
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
EP1071668B1 (en) 1998-04-21 2009-06-03 Bristol-Myers Squibb Pharma Company 5-aminoindeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents
US6407103B2 (en) * 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6559152B2 (en) 1998-10-13 2003-05-06 Dupont Pharmaceuticals Company 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
EP1414804A1 (en) 2000-10-20 2004-05-06 Bristol-Myers Squibb Pharma Company Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors
US6491971B2 (en) 2000-11-15 2002-12-10 G.T. Equipment Technologies, Inc Release coating system for crucibles
US6706718B2 (en) 2000-12-01 2004-03-16 Bristol-Myers Squibb Company 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses
US7605175B2 (en) * 2001-03-02 2009-10-20 Gpc Biotech Ag Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
JP4343534B2 (ja) 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
WO2003004491A1 (en) 2001-07-06 2003-01-16 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses
US20040248905A1 (en) 2001-07-10 2004-12-09 Markwalder Jay A 6-Substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
PL369742A1 (en) * 2001-10-15 2005-05-02 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6753329B2 (en) 2001-12-03 2004-06-22 Gpc Biotech Inc. Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Also Published As

Publication number Publication date
CA2551640A1 (en) 2005-07-14
AU2004309415B2 (en) 2010-08-26
CA2551640C (en) 2012-09-11
BRPI0418095A (pt) 2007-04-17
EA013117B1 (ru) 2010-02-26
IL176543A0 (en) 2006-10-05
US20090209530A1 (en) 2009-08-20
EA200601216A1 (ru) 2006-12-29
MXPA06007399A (es) 2007-01-26
WO2005063765A1 (en) 2005-07-14
HK1101399A1 (zh) 2007-10-18
US8097619B2 (en) 2012-01-17
KR101155883B1 (ko) 2012-06-20
KR20060130624A (ko) 2006-12-19
EP1709051A1 (en) 2006-10-11
JP2007516296A (ja) 2007-06-21
AU2004309415A1 (en) 2005-07-14
NO20063186L (no) 2006-09-20

Similar Documents

Publication Publication Date Title
KR20200038545A (ko) 스플라이싱을 조절하는 방법 및 조성물
US20080146555A1 (en) Uses of Kinase Inhibitors and Compositions Thereof
JP2005511535A (ja) サイクリン依存性キナーゼの阻害剤、組成物及びその使用
JP2018508563A (ja) Ｕｓｐ７阻害剤化合物及び使用方法
JP2004524277A (ja) アシルセミカルバジド及びサイクリン依存性キナーゼ（ｃｄｋ）阻害剤としてのその使用
JP4791975B2 (ja) サイクリン依存性キナーゼの阻害剤、組成物およびそれに関連する使用
US7893057B2 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US6753329B2 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
US7605175B2 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
HK1101399B (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto
CN100471858C (zh) 依赖细胞周期蛋白的激酶抑制剂及其组合物和相关用途
AU2002361570A1 (en) Inhibitors of cyclin-dependent kinases, compositions and uses related thereto

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110722

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140729

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees